Markets:

Overview

News

Currencies

International

Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

101.76 +0.02 (+0.02%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 16, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Corporation - Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors

September 29, 2022

Via AB Newswire

FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests ↗

September 27, 2022

Via Benzinga

COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns ↗

September 23, 2022

The World Health Organization (WHO) warned that it struggles to identify and

Via Benzinga

Expert Ratings for Exact Sciences ↗

August 03, 2022

Within the last quarter, Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings:

Via Benzinga

7 Nasdaq Stocks to Buy on the Dip or You’ll Be Kicking Yourself Later ↗

September 21, 2022

Investors should consider buying these Nasdaq stocks on the dip while they still can before the market reverses higher.

Via InvestorPlace

No More Free COVID-19 At-Home Tests, Federal Government Says ↗

August 29, 2022

CNBC reported that the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, without congressional au

Via Benzinga

What 9 Analyst Ratings Have To Say About Exact Sciences ↗

August 25, 2022

Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings within the last quarter:

Via Benzinga

5 Top Stocks Cathie Wood Bought This Week ↗

August 05, 2022

Cathie Wood continues to increase positions in some of her top stocks despite recession fears. She bought names like EXAS and PACB this week.

Via InvestorPlace

Expert Ratings for Exact Sciences ↗

June 03, 2022

Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings within the last quarter:

Via Benzinga

Non-COVID Sales Boost Exact Sciences' Q1 Revenue; Revises FY22 Guidance ↗

April 27, 2022

Via Benzinga

Earnings Scheduled For April 26, 2022 ↗

April 26, 2022

Companies Reporting Before The Bell • First American Financial (NYSE:FAF) is estimated to report quarterly loss at $0.09 per share on revenue of $46.41 million.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022 ↗

August 25, 2022

Upgrades

Via Benzinga

Cathie Wood Sheds $5M In CRISPR Therapeutics, Scoops Up These Biotech Stocks Instead ↗

August 05, 2022

Cathie Wood-led Ark Investment Management on Thursday sold 70,723 shares of gene editing company CRISPR Therapeutics AG (NASDAQ: CRSP), valued at over $5.58 million, via its flagship fund.

Via Benzinga

Analyst Ratings for Exact Sciences ↗

April 19, 2022

Within the last quarter, Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings:

Via Benzinga

Exact Sciences: Q2 Earnings Insights ↗

August 02, 2022

Exact Sciences (NASDAQ:EXAS) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Exact Sciences beat estimated...

Via Benzinga

Small Cap Biotech Stocks Are Trending Well ↗

July 18, 2022

Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx.

Via Talk Markets

6 Cathie Wood Stocks to Buy on the Dip ↗

July 14, 2022

As major holdings in her portfolios, these Cathie Wood stocks to buy on the dips are likely to significantly pop when the market recovers.

Via InvestorPlace

5 Cathie Wood Stocks to Buy in June ↗

June 09, 2022

These are the five best Cathie Wood stocks to buy in June. EXAS, IONS, KTOS, TRMB, and PATH can make excellent investments.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022 ↗

June 03, 2022

Via Benzinga

Why Ark Innovation ETF Hit 52-Week Lows Today ↗

May 09, 2022

ARK Innovation ETF (ARCA:ARKK) is making new 52-week lows on Monday, led by sharp declines in the top holdings of Ark's flagship fund.

Via Benzinga

9 Health Care Stocks With Whale Alerts In Today's Session ↗

May 06, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Exact Sciences's Return On Capital Employed Insights ↗

April 28, 2022

According to data from Benzinga Pro, during Q1, Exact Sciences's (NASDAQ:EXAS) reported sales totaled $486.57 million. Despite a 17.98% increase in earnings, the company posted a loss of $180.94...

Via Benzinga

SVB Leerink Maintains Outperform Rating for Exact Sciences: Here's What You Need To Know ↗

April 27, 2022

SVB Leerink has decided to maintain its Outperform rating of Exact Sciences (NASDAQ:EXAS) and lower its price target from $130.00 to $95.00. Shares of Exact Sciences are trading up 7.86% over the last...

Via Benzinga

Here's How Much You Would Have Made Owning Exact Sciences Stock In The Last 10 Years ↗

April 27, 2022

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 10 years by 7.98% on an annualized basis producing an average annual return of 19.54%. Currently, Exact Sciences has a market...

Via Benzinga

Preview: Exact Sciences's Earnings ↗

April 25, 2022

Exact Sciences (NASDAQ:EXAS) is set to give its latest quarterly earnings report on Tuesday, 2022-04-26. Here's what investors need to know before the announcement. Analysts estimate that Exact...

Via Benzinga

Here's How Much $1000 Invested In Exact Sciences 20 Years Ago Would Be Worth Today ↗

April 06, 2022

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 20 years by 2.83% on an annualized basis producing an average annual return of 10.04%. Currently, Exact Sciences has a market...

Via Benzinga

How do Biotechnology Funds and ETFs Perform Over Five Years? ↗

March 21, 2022

Biotech investing can be difficult for short-term traders but can offer good returns over five years if balanced with other healthcare positions like the XLV.

Via Talk Markets

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much ↗

March 17, 2022

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 5 years by 12.08% on an annualized basis. Buying $100 In EXAS: 5 years ago, an investor could have...

Via Benzinga

Tesla, Coinbase, Exact Sciences And More: How Cathie Wood's Top 10 Bets Are Faring In 2022 So Far ↗

March 14, 2022

Via Benzinga

Where Exact Sciences Stands With Analysts ↗

February 23, 2022

Over the past 3 months, 4 analysts have published their opinion on Exact Sciences (NASDAQ:EXAS) stock. These analysts are typically employed by large Wall Street banks and tasked...

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.